EMBIOSYS

The Future of Cancer Therapy is Wearable



embiosys.com North Andover, MA

Highlights

1. Efinia™ is a novel, patented, scalable platform technology representing a large market opportunity
2. $2.65 Million in non-dilutive funding awarded to date from the National Cancer Institute
3. Experienced cross-functional team and business partners
4. Compelling pre-clinical evidence and peer reviewed publications
5. Excellent safety profile: Non-invasive, low power, no adverse events in pre-clinical studies
6. Standard distribution path from demand...to order...to patient
7. Product design & manufacturing activities completed with inventory to support human clinical trials
8. Clear clinical development plan to reach product launch in an area of high unmet medical need

Featured Investor



Leonid Bafitos Follow

Syndicate Lead

Invested $5,000

I'm a Senior Engineering Manager with a Master's degree and 14+ years in medical device product development, helping bring complex technologies from early concept to validation and regulatory approval.

"Cancer treatment has advanced tremendously in recent years, yet many patients still face therapies that are physically and emotionally difficult to endure. I am motivated by solutions that not only improve clinical outcomes, but also the patient's quality of life during treatment.

Efinia's approach of delivering cancer therapy in the form of a non-invasive wearable offers patients a fundamentally different experience. The potential to provide an impactful cancer treatment without relying solely on drugs or invasive procedures is what convinced me that this mission is unique.

I am especially encouraged that EMBioSys recently received a Direct-to-Phase II award from the National Cancer Institute, which speaks to the rigor of the team's scientific approach and their thoughtful engagement with the clinical and regulatory pathway.

I'm leading this round because I believe patients deserve better options, and because this impressive and dedicated team is developing technology with both compassion and precision in mind."

& 14 more

Team



Chris Barron Chief Executive Officer



Medical Device Industry Executive with over 35 years of experience including five previous startups in Product Development and Commercialization



Vish Subramaniam Co-Founder, President and Chief Scientific Officer

Academy and Emeritus Professor of Mechanical & Aerospace Engineering and Chemical Physics, The Ohio State University



Jennifer Herron, MBA Independent Director and Strategic Advisor

Biopharma executive with over 30 years of Development and Launch experience in Oncology and Immunology



Joe Camardo, MD Medical Advisor

Board-Certified Internal Medicine Physician with over 40 years of experience in multiple areas, including clinical research, medical affairs, and Chief Medical Officer



Sachin Jhawar Medical Advisor

Specializes in radiation oncology, with focus on breast, skin, head and neck cancers

Empowering patients and providers with a new standard of cancer care


EMBioSys has developed Efinia™, a revolutionary wearable platform with the potential to dramatically improve clinical outcomes as a new cancer treatment modality.

We are focused on addressing high areas of unmet need for treatment of breast cancer as we continue to expand the platform for treatment of other types of cancer.


Currently, over 200,000 women diagnosed with early-stage breast cancer per year in the U.S. go directly to surgery as their first line of treatment.

Unfortunately, scheduling of these surgeries is trending out 30, 60 and even 90 days due to multiple factors within our health care system today.

Based on recent publications including a large study of over 1 million patients, for every 30-day interval of delay to surgery there is an increased risk for tumor growth and spread to the lymph nodes that can lead to surgical complications and a more challenging post-surgery treatment plan. This is a significant problem.







Imagine that patients can treat their cancer, while waiting for surgery at home, without side effects!

This is the potential of Efinia™.




The Efinia™ system* delivers iEF Therapy in the form of a tank top. The patient simply wears the tank top while at home or on the go to receive the therapy. No electrodes are required, and the tank top is machine washable!



*Efinia™ is an investigational device not cleared by the FDA

As a platform technology, Efinia™ is easily scalable to address a large patient population in addition to breast cancer, such as thoracic and abdominal cancers.




EMBioSys will create a seamless process and path from prescription to patient for Efinia™.



Our Story

EMBioSys was founded in 2022 with a mission to develop innovative bioelectric solutions that transform the future of cancer care. Our ultimate vision is to empower patients and providers with a new standard of cancer care.

EMBioSys has experienced tremendous growth in key areas of the business over the last 18 months.



EMBioSys has built a strong cross-functional team experienced in commercialization, product development, operations, clinical, quality, regulatory, and finance.

The company has also established key relationships with health care providers at cancer centers around the country, and has partnered with an impressive team of contractors to support ongoing operations including engineering, manufacturing, corporate IP/legal, and accounting.



Join us on this important mission!

Our Wefunder community round will fund human clinical trials to support our initial commercial pathway for breast cancer patients awaiting surgery as their first line of treatment.

For more information about the science and our technology including publication download links, please visit our website at https://embiosys.com.